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Abstract  Refractory  celiac  disease  is  an  uncommon  but  serious  complication  of  celiac  dis-
ease. We  describe  a  case  of  a  severe  refractory  celiac  disease  type  II,  complicated  with
ulcerative jejunoileitis,  in  a  68  years  old  female,  unresponsive  to  consecutive  treatments
with budesonide,  prednisolone,  cladribine  and  autologous  stem  cell  transplantation.  The
patient maintained  severe  malnutrition,  advanced  osteoporosis,  anaemia,  vitamin  deﬁcien-
cies and  hydro-electrolytic  imbalances,  necessitating  consecutive  hospitalizations  for  total
parenteral  nutrition.  The  patient  also  developed  life-threatening  complications,  namely  respi-
ratory and  urinary  septic  shock  and  also  episodes  of  haemorrhagic  shock  secondary  to  ulcerative
jejunoileitis.  The  progression  to  enteropathy  associated  T-cell  lymphoma  was  never  demon-
strated, but  the  patient  died  7  years  after  the  diagnosis  due  to  a  septic  shock  secondary  to
a nosocomial  pneumonia  and  osteomyelitis  related  to  a  spontaneous  hip  fracture.  This  case
highlights the  difﬁculties  in  the  diagnostic  process,  therapeutic  management  and  surveillance
of this  rare  condition  associated  with  very  poor  prognosis.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail address: xanafmuc@hotmail.com (A. Fernandes).
1 Present address: Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal.
ttp://dx.doi.org/10.1016/j.jpge.2015.08.001
341-4545/© 2015 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier España, S.L.U. This is an open access article under the
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Case  Report  of  Refractory  Celiac  Disease  107
PALAVRAS-CHAVE
Cladribina;
Doenc¸a  Celíaca;
Transplante  de
Células  Estaminais
Hematopoiéticas;
Linfoma  de  Células  T
Associado  a
Enteropatia
Doenc¸a Celíaca  Refratária  Tipo  II:  Um  Caso  Clínico  que  Ilustra  os  Desaﬁos  Diagnósticos
e  Terapêuticos
Resumo  A  doenc¸a  celíaca  refratária  é  uma  complicac¸ão  rara  mas  muito  severa  da  doenc¸a
celíaca.  Apresentamos  o  caso  de  uma  doente  de  68  anos,  com  doenc¸a  celíaca  refratária  tipo  II
complicada  de  jejunoileíte  ulcerativa,  que  não  respondeu  a  tratamentos  sucessivos  com  budes-
onido, prednisolona,  cladribina  e  transplante  autólogo  de  medula  óssea.  A  doente  manteve
desnutric¸ão e  osteoporose  severas,  deﬁciências  vitamínicas  e  desequilíbrios  hidro-eletrolíticos,
necessitando  de  múltiplas  hospitalizac¸ões  para  receber  nutric¸ão  parentérica  total.  Também
desenvolveu  diversas  complicac¸ões  potencialmente  fatais  nomeadamente  sépsis  com  origem
respiratória  e  urinária  e  choque  hemorrágico  secundário  à  jejunoileíte  ulcerativa.  Contudo,
nunca se  demonstrou  a  presenc¸a  de  um  linfoma  de  células  T.  A  doente  faleceu  7  anos  após  o
diagnóstico  devido  a  choque  sético  secundário  a  pneumonia  nosocomial  e  osteomielite  rela-
cionada com  fratura  espontânea  da  anca.  Este  caso  ilustra  as  diﬁculdades  sentidas  no  decurso
do diagnóstico,  terapêutica  e  vigilância  desta  entidade  clínica  rara,  a  qual  está  associada  a  um
péssimo prognóstico.
©  2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
n
s
d
c
n
p
F
a
S
1
e
h
(
m
G
e
i
m
a
3
g
z
I
m
e
d
t
t
p
a
m
I
b
w1. Introduction
Celiac  disease  (CD)  is  a  chronic  immune-mediated  enteropa-
thy  precipitated  by  exposure  to  dietary  gluten  in  genetically
predisposed  individuals.  It  is  a  common  autoimmune  dis-
ease  affecting  around  1%  of  the  general  population.1 The
diagnosis  is  often  easy  in  the  presence  of  classic  symptoms
of  malabsorption,  positive  celiac-speciﬁc  antibodies  and  vil-
lous  atrophy  in  duodenal  biopsies.  However,  some  patients,
mainly  those  diagnosed  in  the  adulthood,  can  only  present
atypical  or  extra  intestinal  manifestations  (e.g.  iron  deﬁ-
ciency,  fatigue,  abnormal  liver  function  tests,  bone  disease,
skin  disorders,  peripheral  neuropathy,  depression),  and  the
speciﬁc  serology  can  be  negative.2,3 Strict  life-long  gluten
free  diet  (GFD)  is  the  only  treatment  available,  leading  to
clinical  and  mucosal  recovery  in  most  patients,  but  a  small
minority  does  not  show  clinical  improvement  upon  GFD.1,4
Refractory  CD  (RCD)  is  a  rare  and  severe  condition,  devel-
oping  in  1--5%  of  the  adult-onset  CD  patients,  and  is  deﬁned
as  persistent  or  recurrent  symptoms  and  signs  of  malabsorp-
tion  with  small  intestinal  villous  atrophy  despite  a  strict  GFD
for  more  than  12  months  in  the  absence  of  other  causes  of
villous  atrophy.5,6 RCD  is  divided  in  two  types  based  on  the
absence  (Type  I)  or  presence  (Type  II)  of  abnormal  intraep-
ithelial  lymphocytes  (IEL).7 Type  II  RCD  (RCD-II)  has  limited
therapeutic  options,  often  complicates  with  severe  malnu-
trition,  ulcerative  jejunoileitis  and  enteropathy  associated
T-cell  lymphoma  (EATL).7,8
We  report  an  unfavourable  case  of  RCD-II,  describing
the  difﬁculties  in  the  initial  diagnosis,  the  consecutive
failures  of  distinct  therapeutic  options,  and  the  multiple
complications  that  ﬁnally  led  to  the  death  of  the  patient.2. Case report
We  present  the  case  of  a  68  years  old  white  female,  diag-
nosed  with  CD  in  2008,  when  she  was  61  years  old,  and  whom
c
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Cever  become  asymptomatic  despite  strict  GFD.  The  diagno-
is  was  made  considering  characteristic  histologic  features,
espite  negative  speciﬁc-CD  serology.  She  had  no  other
omorbidities  apart  from  chronic  depression  and  there  was
o  family  history  of  CD  or  other  autoimmune  diseases.  The
atient  presented  to  our  department  for  the  ﬁrst  time  in
ebruary  2010  complaining  of  chronic  diarrhoea,  vomiting,
norexia,  asthenia  and  weight  loss,  despite  2  years  of  GFD.
he  showed  severe  malnutrition  (body  mass  index  --  BMI:
2  kg/m2,  extreme  hypoalbuminemia),  threatening  hydro-
lectrolytic  imbalances  (hypomagnesaemia,  hypokalaemia,
ypophosphatemia,  hypocalcaemia),  normocytic  anaemia
haemoglobin  of  8.1  g/dL),  coagulopathy  (INR  of  8.2),  vita-
in  deﬁciencies  and  severe  osteoporosis.  The  adherence  to
FD  was  revised  and  ensured.  Upper  gastrointestinal  (UGI)
ndoscopy  with  duodenal  biopsies  was  repeated,  show-
ng  endoscopic  aspects  compatible  with  CD  (Fig.  1).  A
arked  villous  atrophy,  with  villous  to  crypt  ratio  of  <1/1
nd  increased  IEL  were  observed  --  Marsh-Oberhuber  stage
b  (Fig.  2).  These  biopsies  also  allowed  the  diagnosis  of
iardiasis  that  was  successfully  treated  with  metronida-
ole  (conﬁrmed  with  repeated  biopsies  after  treatment).
leocolonoscopy  was  performed,  and  despite  absence  of
ucosal  changes  random  biopsies  demonstrated  the  pres-
nce  of  lymphocytic  colitis.  Apart  from  these  two  parallel
iagnoses  that  could  contribute  to  the  refractory  symp-
oms,  careful  investigation  and  exclusion  of  other  entities
hat  could  be  the  cause  of  symptoms  and  villous  atro-
hy  was  made  (Table  1).  Speciﬁc-CD  serology  was  repeated
nd  it  was  negative  once  again.  HLA  typing  was  deter-
ined  and  revealed  a  DQ2/DQ8  compound  heterozygote.
mmunohistochemical  analysis  was  performed  in  duodenal
iopsies  and  revealed  more  than  50%  of  aberrant  IELs,  which
ere  CD3+,  but  mostly  CD8-  and  CD30-  (Fig.  3),  being
ompatible  with  a  RCD-II,  with  no  evidence  of  EATL.  The
berrant  pattern  was  conﬁrmed  by  detection  of  T-cell  recep-
or  chains  clonal  rearrangement,  performed  at  the  Celiac
entre  Amsterdam,  VU  University  Medical  Centre.  A  CT  scan
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Table  1  Other  causes  of  non-responsive  celiac  disease  (NRCD)  and  villous  atrophy  in  adults  that  were  investigated/excluded.
Differential  diagnosis Investigation/Evidence
Other  causes  of  NRCD
Gluten  contamination  Exclusion  by  extensive  nutritional  revision  (expert  dietician);  hospitalization
Microscopic  colitis  Successfully  treated  with  resolution  on  repeated  colonic  biopsies
Bacterial  overgrowth  Unresponsive  to  multiple  antibiotic  courses
Lactose intolerance Unresponsive  to  lactose  eviction
Pancreatic  insufﬁciency Normal  faecal  elastase
Irritable  bowel  syndrome Clinical  course  and  severity  not  compatible
Other causes  of  duodenal  villous  atrophy
Giardiasis  Successfully  treated;  resolution  on  repeated  duodenal  biopsies
Crohn’s disease  Negative  ASCA  and  ANCA;  Histology  not  compatible
Infectious enteritis  Consecutive  negative  serologies  and  faecal  cultures
Parasitic infestation  Consecutive  negative  stool  parasitic  analysis
AIDS enteropathy  Negative  HIV  1  +  2
Eosinophilic  gastroenteritis  Histology  not  compatible
Whipple  disease  Histology  not  compatible
Intestinal  tuberculosis  Absence  of  Micobacterium  tuberculosis  in  duodenal  biopsies;  Negative
QuantiFERON
Collagenous sprue  Absence  of  subepithelial  collagen  deposition  band
Tropical  sprue  Absence  of  travel  history  to  endemic  areas  and  no  improvement  with  folic  acid
and antibiotics
Intestinal  lymphoma Normal  2  microglobulin;  Exclusion  on  intraoperative  enteroscopy  and  jejunal
biopsies
Adult-onset autoimmune  enteropathya Signiﬁcative  intraepithelial  lymphocytosis  is  against  this  diagnosis  (it  would  be
expected  reduced  number  of  IEL);  positive  HLA  DQ2/DQ8  is  not  typical  of  this
condition
Hypogammaglobulinemia  Normal  serum  immunoglobulin  and  protein  electrophoresis;  no  major  changes  in
thoracic  CT  scan;  no  history  of  recurrent  infections
Small-bowel  ischaemia  Histology  not  compatible
Drug-associated  enteropathy  No  history  of  suspicious  medication
a Determination of anti-enterocyte or anti-goblet cell antibodies was not possible in our institution.
Figure  1  Upper  gastrointestinal  endoscopy,  showing  classic
endoscopic  signs  of  villous  atrophy  such  as  loss  of  Kerckring’s
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Figure  2  Biopsies  from  the  distal  duodenum  (H&E)  showing
severe  villous  atrophy  together  with  intraepithelial  lympho-olds in  the  duodenum,  ﬁssuring  with  a  mosaic  pattern,  and  also
 small  ulcer.nteroclysis  identiﬁed  bowel-wall  thickening  in  the  jejunum
nd  ileum,  mesenteric  lymphadenopathy  and  prominent
esenteric  vessels  resembling  the  comb  sign  (Fig.  4).  Unfor-
unately,  the  double  ballon  enteroscopy  performed  was  not
cytosis (>40  IELs/100  enterocytes)  and  crypt  hyperplasia  --
Marsh-Oberhuber  type  3b.
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satisfactory  and  could  not  ﬁnd  these  abnormalities.  Addi-
tionally,  the  videocapsule  enteroscopy  revealed  ﬂat  mucosa,
scalloping  effect  and  multiple  small  ulcers,  particularly
in  the  jejunum  (Fig.  5).  Apart  from  total  parenteral
nutrition  (TPN)  with  correction  of  ionic  and  vitamin  deﬁ-
ciencies,  and  after  antibiotic  therapy  to  treat  the  giardiasis,
the  patient  started  budesonide  (9  mg/i.d.)  that  was  ade-
quate  not  only  for  the  RCD  but  also  for  the  lymphocitic
colitis  treatment,  yet  due  to  insufﬁcient  improvement
prednisolone  was  initiated  (1  mg/kg  weight).  The  clinical
response  was  unsatisfactory  and  consecutive  hospitaliza-
tions  were  necessary  to  perform  TPN  and  hydro-electrolytic
corrections.  Due  to  lack  of  response  to  budesonide  and
prednisolone  an  intraoperative  enteroscopy  was  performed
and  an  ulcerative  jejunoileitis  was  identiﬁed,  corroborat-
ing  the  diagnosis  of  RCD-II.  The  case  was  discussed  and
reviewed  by  experts  in  CD  at  Celiac  Centre  Amsterdam,
VU  University  Medical  Centre  that  agreed  with  the  diag-
nosis  of  RCD-II  and  suggested  treatment  with  cladribine,
which  was  performed  in  October  2010  (single  cycle,  intra-
venous,  0.1  mg/kg/day  for  5  days),  with  good  clinical,
analytical  and  nutritional  response  (BMI:  20  kg/m2),  keep-
ing,  however,  a  Marsh-Oberhuber  stage  3b.  In  April  2011,  6
months  after  cladribine,  there  was  a  new  clinical  deterio-
ration  and  TPN  was  again  initiated.  The  patient  was  then
proposed  for  autologous  stem  cell  transplantation  (ASCT),
performed  in  October  2011,  with  no  histological  improve-
ment  but  with  some  clinical  stability  until  December  2013.
Since  then  the  patient  was  consecutively  hospitalised  due  to
severe  malnutrition  (BMI  <  14  kg/m2),  vitamin  deﬁciencies,
hydro-electrolytic  imbalances  and  anaemia,  necessitating
TPN  and  blood  transfusions,  and  also  respiratory  and  uri-
nary  infections  complicated  with  septic  shock,  and  episodes
of  haemorrhagic  shock.  There  was  also  a  spontaneous  frac-
ture  of  the  femur  neck,  secondary  to  severe  osteoporosis,
treated  with  a  dynamic  hip  screw  (DHS)  that  infected  sub-
sequently  and  needed  to  be  removed.  The  patient  died  7
years  after  the  diagnosis  of  CD,  due  to  a  respiratory  septic
shock,  presenting  with  severe  malnutrition  (BMI  10  kg/m2),
without  evidence  of  EATL  on  CT  scan  enteroclysis  and  PET
scan.
3. Discussion
Celiac  disease  is  a  common  autoimmune  condition  that  is
generally  associated  with  good  prognosis  as  the  compliance
of  a  strict  GFD  leads  to  clinical  and  mucosal  recovery.1
When  diagnosed  in  adults,  particularly  above  the  age  of  50,
the  presentation  is  often  atypical  and  lack  of  improvement
under  GFD  is  more  likely.4 Iron  deﬁciency  and  extraintesti-
nal  manifestations  (like  bone  disease  and  depression)  can
be  the  only  presenting  signs  of  the  disease,  and  deﬁnitive
diagnosis  is  normally  delayed.9 At  this  stage,  the  diagnostic
workup  is  signiﬁcantly  more  complex,  especially  in  cases  of
seronegative  CD.  In  our  particular  case,  although  the  clin-
ical  suspicion  and  the  ﬁrst  duodenal  biopsies  (taken  while
the  patient  was  on  normal  diet)  corroborated  the  diagnosis
of  CD,  there  were  two  major  problems  --  negative  celiac-
speciﬁc  antibodies  performed  while  on  a  gluten-containing
diet  and  unresponsiveness  to  GFD.  In  cases  of  non-responsive
CD  (NRCD),  after  ensuring  strict  adherence  to  GFD,  the  ﬁrst
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tep  is  to  conﬁrm  the  initial  diagnosis  of  CD  and  exclude
ther  entities  that  mimic  CD  symptoms  and  other  causes
f  villous  atrophy.  The  positivity  of  celiac-speciﬁc  antibod-
es  is  one  of  the  parameters  used  to  conﬁrm  the  diagnosis,
ut  serology  may  be  negative  in  5--16%  of  patients  with
iopsy-conﬁrmed  CD.2,3,5 This  was  the  case  of  our  patient
hat  despite  negative  speciﬁc  serology  presented  typical
istology  and  high  clinical  suspicion.  In  these  ambiguous
eronegative  CD  cases  HLA  typing  may  help  to  rule  out
r  conﬁrm  the  diagnosis,  as  HLA-DQ2  (≈95%)  or  HLA-DQ8
≈5%)  are  present  in  almost  all  patients  with  CD.10,11 So,
D  is  excluded  for  patients  who  are  negative  for  HLA-DQ2
r  HLA-DQ8,  considering  its  high  negative  predictive  value
>99%).12,13 In  fact,  our  patient  presented  HLA  DQ2/DQ8
ompound  heterozygosity,  supporting  the  CD  diagnosis.
NRCD  is  common,  affecting  from  7%  to  30%  of  patients
nder  GFD.  There  are  many  distinct  aetiologies  including
nadvertent  gluten  ingestion  (the  most  common  cause),
ther  food  intolerances,  small  intestinal  bacterial  over-
rowth,  microscopic  colitis,  pancreatic  insufﬁciency  and
CD,  that  makes  up  a  small  subset  (approximately  10%)
f  NRCD.14--16 In  fact,  during  the  extensive  investigation
o  exclude  other  potential  causes  of  chronic  diarrhoea
Table  1),  we  identiﬁed  two  concomitant  entities  --  micro-
copic  colitis  and  giardiasis  --  that  could  be  responsible  for
ome  persisting  symptoms,  but  despite  being  successfully
reated,  the  severe  symptoms  persisted.  Moreover,  these
re  two  common  conditions  associated  with  CD,  particularly
icroscopic  colitis  that  develops  in  4%  of  patients  with  CD.9
RCD  is  almost  exclusive  of  patients  diagnosed  with
D  above  the  age  of  50,  and  two  to  three  times  more
requent  in  women.7 Our  patient  had  all  these  epi-
emiological  features.  The  immunohistochemical  studies
s  well  as  a  T-cell  receptor  gene  rearrangement  analy-
is  showing  clonal  expansion  were  indicative  of  RCD-II.7
his  diagnosis  was  further  supported  by  the  presence  of
evere  and  life  threatening  malnutrition,  protein  losing
nteropathy,  bowel-wall  thickening  in  the  jejunum/ileum
nd  mesenteric  lymphadenopathy  at  CT  scan  enteroclysis
nd,  most  important,  evidence  of  ulcerative  jejunoileitis,
hat  should  be  considered  synonym  of  RCD-II.8,17,18 When
here  are  doubts  about  the  diagnosis  in  immunohisto-
hemical  and/or  T-cell  receptor  gene  rearrangement,  ﬂow
ytometry  is  a  good  option,  since  it  is  able  to  differ-
ntiate  cytoplasmatic  from  membranous  CD3  expression
nd  to  identify  other  aberrant  IEL  with  preserved  CD8
xpression.7 EATL  is  a  threatening  complication  and  was
 major  concern  in  this  patient,  considering  the  clinical
everity  and  lack  of  sustained  response  to  medical  treat-
ent.  However,  its’  presence  was  systematically  excluded
n  multiple  histological  analyses.  Additionally,  the  aberrant
ELs  of  our  patient  lack  CD30  expression  that  is  associated
ith  worse  prognosis,  including  the  development  of  overt
ATL.19
RCD-II  has  a  poor  prognosis,  with  a  ﬁve-year  survival
etween  44  and  58%.  The  higher  mortality  can  be  largely
ttributed  to  the  high  risk  of  developing  EATL,  which  occurs
etween  33%  and  52%  within  5  years  after  diagnosis.7 Even  in
he  absence  of  EATL  RCD-II  is  often  complicated  with  threat-
ning  haemorrhage  due  to  ulcerative  jejunoileitis,  severe
alabsortion  with  intestinal  failure  and  severe  sepsis,  as
ccurred  in  our  patient.5,9
110  A.  Fernandes  et  al.
Figure  3  Immunohistochemistry  images  from  the  duodenal  biopsies  showing  an  abnormal  population  of  IELs  which  are  (A)  CD3
positive, but  (B)  mostly  CD8  negative  and  (C)  CD30  negative.
Figure  4  CT  scan  enteroclysis,  showing  bowel-wall  thickening,  mesenteric  lymphadenopathy  and  prominent  mesenteric  vessels
resembling the  comb  sign.
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ligure  5  Videocapsule  enteroscopy  images  showing  grossly  o
lcer.
As  RCD-II  is  a  rare  disease,  to  date  there  is  no  stan-
ardised  therapy,  and  the  evidence  for  treatment  is  based
n  case  reports,  open-label  observational  or  prospective
xperiences,  and  expert  opinion.17 Apart  from  TPN  and  sub-
titution  of  vitamins,  that  are  consensual,  pharmacological
herapy  is  question  of  debate.  Immunosuppressive  drugs  sug-
ested  for  RCD-I  include  steroids,  thiopurines,  cyclosporine,
nﬂiximab  and  alemtuzumab.8,17 Steroids  suppress  clinical
ymptoms  in  RCD-I  and  clinical  improvement  is  reported  in
p  to  90%  of  patients.8 However,  RCD-II  is,  at  least  in  part,
esistant  to  most  therapies  evaluated  so  far  and  there  is
t
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gatous  jejunum  with  ﬂat  mucosa,  scalloping  effect  and  a  small
o  place  for  immunosuppressive  drugs  such  as  azathioprine
nd  inﬂiximab,  that  could  increase  the  risk  of  progression  to
ATL.4,8,17 Cladribine  is  equally  toxic  to  proliferating  as  to
ondividing  lymphoid  cells,  and  this  feature  is  particularly
nteresting  for  the  treatment  of  low-grade  malignancies,
s  RCD-II  is  considered,  and  there  are  already  some  pub-
ished  cases  with  favourable  results.7,20 We  decided  to  use
his  strategy  in  our  patient  but  it  did  not  lead  to  sustained
mprovement.  Finally,  high-dose  chemotherapy  followed  by
SCT  has  been  explored  for  RCD-II  in  a  pilot  study  from  a  sin-
le  centre.21 This  was  our  last  alternative,  but  unfortunately
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it  did  not  bring  sustained  clinical  or  histological  improve-
ments.  Interleukin-15  blockade  could  also  be  considered  as
an  experimental  therapy.22
Surgery  in  RCD  should  be  limited  to  the  management  of
complications  such  as  perforation,  massive  haemorrhage,
high-grade  obstruction,  and  cancer.8,23
The  present  case  also  emphasises  the  uncertainties
regarding  the  optimal  follow-up  strategy  of  patients  with
RCD-II.  Regular  follow-up,  including  UGI  endoscopy  with
biopsies,  CT  scan  or  MR  enteroclysis,  and  PET  scan,  is  nec-
essary  to  detect  EATL  as  early  as  possible.7 However,  the
best  tests  for  EATL  surveillance  and  the  appropriate  inter-
val  between  examinations  are  not  currently  established.8
Clinical  supervision  in  RCD  should  not  be  limited  to  EATL
surveillance  but  should  also  include  monitoring  for  nutri-
tional  deﬁciencies  and  bone  density  measurements.
This  RCD-II  case  demonstrates  the  difﬁculties  in  the  diag-
nosis,  management  and  surveillance  of  this  rare  condition.
The  therapeutic  approach  is  complex,  since  there  are  few
options,  whose  efﬁcacy  is  not  yet  fully  demonstrated,  and
which  are  not  sufﬁciently  validated.
In  our  opinion,  due  to  rarity  of  RCD,  these  patients
should  be  referred  to  specialised  centres.  International  con-
sensuses  in  these  areas  are  urgently  required  in  order  to
facilitate  future  therapeutic  advances.
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